Literature DB >> 10520349

Rapid epidemiological mapping of onchocerciasis in areas of Uganda where Simulium neavei sl is the vector.

M Katabarwa1, A W Onapa, B Nakileza.   

Abstract

OBJECTIVE: To test whether Rapid Epidemiological Mapping of Onchocerciasis (REMO) was suitable for mapping of onchocerciasis in foci where S. neavei sl is the primary vector.
DESIGN: Topographical maps of scale 1:250,000 were used in demarcating regions into ecotopographic divisions and zones in order to identify potential onchocerciasis endemic areas.
SETTING: The study was conducted in Kabarole and Nebbi districts. High-risk communities were selected 30 km from each other, and closest to rivers where vector breeding appeared likely. Secondary and additional communities were selected 10 km and 20 km away from high-risk communities, respectively. SUBJECTS OR PARTICIPANTS: Communities were mobilised for nodule palpation. A sample of thirty males aged at least 20 years, from each community that had lived in the area for at least ten years, were randomly selected and examined.
INTERVENTIONS: Individuals positive for at least one nodule were expressed in terms of Nodule Prevalence Rates (NPR) which were used to map the distribution of onchocerciasis. MAIN OUTCOME MEASURES: Coefficient of variation (CV) of Nodule Prevalence Rates between high risk secondary communities.
RESULTS: In Kabarole district, the results indicated a low coefficient of variation (CV) of 75 in NPR between high risk and secondary communities while in Nebbi district, higher CV of 187.4 was attained. The less varied NPR implies that communities in Kabarole were almost equally exposed to onchocerciasis while highly varied situation in Nebbi indicated decreasing NPR with increasing distance from high-risk communities.
CONCLUSION: REMO is applicable in areas where S. neavei sl is the primary vector, for identification and mapping communities requiring mass treatment with ivermectin.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Community; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Epidemiology; Geographic Factors; Health; Onchocerciasis; Parasitic Diseases; Population; Public Health; Research Report; Residence Characteristics; Spatial Distribution; Uganda

Mesh:

Substances:

Year:  1999        PMID: 10520349

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  12 in total

1.  Seventeen years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in North Region, Cameroon.

Authors:  Moses N Katabarwa; Albert Eyamba; Philippe Nwane; Peter Enyong; Souleymanou Yaya; Jean Baldiagaï; Théodore Kambaba Madi; Abdoulaye Yougouda; Gervais Ondobo Andze; Frank O Richards
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

2.  Transmission of Onchocerca volvulus by Simulium neavei in Mount Elgon focus of Eastern Uganda has been interrupted.

Authors:  Moses Katabarwa; Tom Lakwo; Peace Habomugisha; Stella Agunyo; Edson Byamukama; David Oguttu; Richard Ndyomugyenyi; Ephraim Tukesiga; Galex Orukan Ochieng; Francis Abwaimo; Ambrose Onapa; Dennis W K Lwamafa; Frank Walsh; Thomas R Unnasch; Frank O Richards
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

3.  Transmission of Onchocerca volvulus continues in Nyagak-Bondo focus of northwestern Uganda after 18 years of a single dose of annual treatment with ivermectin.

Authors:  Moses N Katabarwa; Tom Lakwo; Peace Habomugisha; Stella Agunyo; Edson Byamukama; David Oguttu; Ephraim Tukesiga; Dickson Unoba; Patrick Dramuke; Ambrose Onapa; Edridah M Tukahebwa; Dennis Lwamafa; Frank Walsh; Thomas R Unnasch
Journal:  Am J Trop Med Hyg       Date:  2013-05-20       Impact factor: 2.345

Review 4.  Global epidemiology, ecology and control of soil-transmitted helminth infections.

Authors:  S Brooker; A C A Clements; D A P Bundy
Journal:  Adv Parasitol       Date:  2006       Impact factor: 3.870

Review 5.  Rapid mapping of schistosomiasis and other neglected tropical diseases in the context of integrated control programmes in Africa.

Authors:  S Brooker; N B Kabatereine; J O Gyapong; J R Stothard; J Utzinger
Journal:  Parasitology       Date:  2009-05-19       Impact factor: 3.234

6.  Transmission of onchocerciasis in wadelai focus of northwestern Uganda has been interrupted and the disease eliminated.

Authors:  Moses N Katabarwa; Frank Walsh; Peace Habomugisha; Thomson L Lakwo; Stella Agunyo; David W Oguttu; Thomas R Unnasch; Dickson Unoba; Edson Byamukama; Ephraim Tukesiga; Richard Ndyomugyenyi; Frank O Richards
Journal:  J Parasitol Res       Date:  2012-08-26

7.  Prevalence of onchocerciasis in the Fundong Health District, Cameroon after 6 years of continuous community-directed treatment with ivermectin.

Authors:  Henri Lucien Fouamno Kamga; Dickson Nsagha Shey; Jules Clement Nguedia Assob; Anna Longdoh Njunda; Peter Nde Fon; Peter Kindong Njem
Journal:  Pan Afr Med J       Date:  2011-11-10

8.  Fifteen years of annual mass treatment of onchocerciasis with ivermectin have not interrupted transmission in the west region of cameroon.

Authors:  Moses N Katabarwa; Albert Eyamba; Philippe Nwane; Peter Enyong; Joseph Kamgno; Thomas Kueté; Souleymanou Yaya; Rosalie Aboutou; Léonard Mukenge; Claude Kafando; Coulibaly Siaka; Salifou Mkpouwoueiko; Demanga Ngangue; Benjamin Didier Biholong; Gervais Ondobo Andze
Journal:  J Parasitol Res       Date:  2013-04-17

Review 9.  Neglected tropical diseases in Uganda: the prospect and challenge of integrated control.

Authors:  Jan H Kolaczinski; Narcis B Kabatereine; Ambrose W Onapa; Richard Ndyomugyenyi; Abbas S L Kakembo; Simon Brooker
Journal:  Trends Parasitol       Date:  2007-09-07

10.  The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (1) priority areas for ivermectin treatment.

Authors:  Mounkaila Noma; Honorat G M Zouré; Afework H Tekle; Peter A I Enyong; Bertram E B Nwoke; Jan H F Remme
Journal:  Parasit Vectors       Date:  2014-07-22       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.